Specialty code 174400000X · Anaheim, CA
NPI
1205802618
Since 2006
Specialty
Specialty code 174400000X
Code 174400000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
1801 W Romneya Dr, Ste#203
Anaheim, CA, 92801
Phone (714) 999-1465
Medicare paid, 2024
$1.2M
49,160 services
Medicare patients, 2024
622
Average age 74
Drug cost, 2024
$5.2M
1,844 prescriptions
Company payments, 2025
$42.23
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ajit S Maniam was code J0897 (injection, denosumab, 1 mg), 3,676 times for 44 patients. In total Ajit S Maniam billed 49,160 services in 84 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-12-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 3,676 | 44 | $20.70 | $76K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,606 | 33 | $0.09 | $145 |
| 99214 Office E&M - Established | Office | 1,114 | 437 | $113.37 | $126K |
| 85025 Blood Count | Office | 835 | 330 | $7.59 | $6,340 |
| 36415 Venipuncture Blood Collection | Office | 779 | 333 | $8.61 | $6,710 |
| 96127 Behavioral Health Services | Office | 356 | 285 | $3.89 | $1,386 |
| 96372 Injection Administration | Office | 334 | 118 | $13.22 | $4,416 |
| 99233 Hospital E&M - Subsequent | Facility | 199 | 77 | $105.18 | $21K |
| 96367 Intravenous Infusion, Hydration | Office | 177 | 34 | $27.57 | $4,880 |
| 96413 Chemotherapy Administration | Office | 166 | 32 | $127.73 | $21K |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 118 | 48 | $1.00 | $118 |
| 99213 Office E&M - Established | Office | 98 | 58 | $84.73 | $8,303 |
| 99232 Hospital E&M - Subsequent | Facility | 92 | 37 | $70.33 | $6,470 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 82 | 30 | $0.64 | $52.14 |
| 96415 Chemotherapy Administration | Office | 75 | 13 | $26.77 | $2,007 |
By year: 2022 $578K for 53,365 services; 2023 $697K for 43,970 services; 2024 $1.2M for 49,160 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 835 | 330 | $7.59 | $6,340 |
| 36415 Venipuncture Blood Collection | 779 | 333 | $8.61 | $6,710 |
Medicare prescription drug claims, 2024
In 2024, the drug Ajit S Maniam prescribed most often to Medicare patients was Procrit (Epoetin Alfa), with 130 prescriptions and refills. In total Ajit S Maniam wrote 1,844 Medicare prescriptions that cost $5.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Procrit Epoetin Alfa | 130 | 132 | 29 | $208K |
| Anastrozole Generic | 112 | 263 | 34 | $2,148 |
| Dexamethasone Generic | 64 | 81 | 23 | $894 |
| Diphenhydramine Hcl Generic | 61 | 63 | 24 | $149 |
| Dexamethasone Sodium Phosphate Generic | 57 | 60 | 24 | $251 |
| Xgeva Denosumab | 56 | 71 | Under 11 | $164K |
| Gabapentin Generic | 55 | 78 | 22 | $745 |
| Lupron Depot Leuprolide Acetate | 54 | 149 | 20 | $298K |
| Revlimid Lenalidomide | 45 | 45 | Under 11 | $785K |
| Zarxio Filgrastim-Sndz | 45 | 45 | 12 | $79K |
| Alendronate Sodium Generic | 40 | 85 | 13 | $265 |
| Keytruda Pembrolizumab | 37 | 37 | Under 11 | $492K |
| Palonosetron Hcl Generic | 36 | 37 | 12 | $2,407 |
| Fosaprepitant Dimeglumine Generic | 33 | 33 | Under 11 | $2,203 |
| Prednisone Generic | 33 | 40 | Under 11 | $120 |
Brand drugs: 731 claims; generic drugs: 1,113 claims; opioid claims: 50.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ajit S Maniam $42.23 ($42.23 in general payments such as food, travel and fees) from 4 companies. The largest payer was Novartis Pharmaceuticals Corporation with $22.44.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.